February 22, 2022

Chameleon Biosciences welcomes Paul Fitzpatrick, Ph.D.

We are very pleased to announce and welcome Paul Fitzpatrick to the Chameleon team as a Vice President of R&D.

In this role, Paul will be responsible for leading Chameleon’s research team in the further development of our EVADER™ platform technology, developing our pipeline programs and facilitating collaborations.

Paul comes to us with more than 20 years of biotech leadership experience in growing teams and advancing innovative therapies. Most recently, Paul has been at Zogenix, with a focus on bioprocessing and CMC execution strategies. Prior to Zogenix, Paul had an impactful 20-year career at BioMarin, where he led the Biologics and Production Group, including scientific and operational responsibility for research stage biologics and AAV production, as well as early stage process analytics and structural, cellular, and protein biology fundamental research.

Paul earned a Ph.D. in applied biochemistry from the Massachusetts Institute of Technology and Bachelor of Science degrees in both biology and chemistry from UC Irvine.